OCT 11, 2019
Macular Disease, Retina/Vitreous
In this interview from AAO 2019, Dr. Charles Wykoff discusses a phase 1b study evaluating the intraocular durability of a novel therapeutic—the anti-VEGF antibody biopolymer conjugate KSI-301—in treatment-naive patients with wet AMD, diabetic macular edema (DME) or retinal vein occlusion (RVO). Each patient received 3 monthly injections of KSI-301, with additional dosing based on disease activity. All three cohorts showed KSI-301 bioactivity, and the trial continues to explore the drug's ability to deliver extended intraocular anti-VEGF activity.
Relevant Financial Disclosures: Dr. Wykoff is a consultant for and receives grant support from Kodiak Sciences.